Actinobacillus Pleuropneumoniae (APP)

Actinobacillus pleuropneumoniae vaccines represent essential tools in the prevention and control of one of the most economically devastating bacterial respiratory diseases affecting commercial swine production worldwide. These vaccines target Actinobacillus pleuropneumoniae, a gram-negative bacterium responsible for porcine pleuropneumonia, a highly contagious disease characterized by severe fibrinous pleuropneumonia that can cause rapid mortality in acute outbreaks and chronic production losses in endemically infected herds. The economic impact of APP infections includes direct mortality, reduced growth performance, increased medication costs, and carcass condemnations at slaughter due to lung lesions.

The mechanism of protection provided by APP vaccines primarily involves stimulation of antibodies against the Apx toxins produced by the bacterium. Actinobacillus pleuropneumoniae produces three main cytotoxic RTX toxins designated ApxI, ApxII, and ApxIII, which are responsible for the severe lung tissue destruction characteristic of the disease. Modern APP vaccines typically contain inactivated toxoids derived from these Apx toxins, stimulating neutralizing antibodies that prevent toxin-mediated tissue damage following bacterial exposure. Some vaccines additionally contain outer membrane proteins and other bacterial antigens to provide broader immune protection.

APP vaccines are available in various formulations designed to address the serotype diversity of Actinobacillus pleuropneumoniae in different geographic regions. At least eighteen serovars of APP have been identified, with varying regional prevalence and virulence characteristics. While Apx toxin-based vaccines provide cross-protection across multiple serovars because different serovars share common toxin production patterns, vaccine selection may consider regional serotype epidemiology for optimal protection. Both monovalent and multivalent products are available depending on market and manufacturer.

Regulatory approval of APP vaccines encompasses multiple products in major swine-producing countries including the United States, European Union, and Asian markets. These vaccines have undergone extensive safety and efficacy evaluation demonstrating their value in reducing clinical disease, mortality, and lung lesion severity following challenge with virulent APP strains. The vaccines are considered core components of respiratory disease prevention programs in operations where APP has been diagnosed or where epidemiological risk factors suggest potential for disease introduction.

The primary indication for APP vaccine administration is prevention of clinical porcine pleuropneumonia in growing pigs at risk of exposure to Actinobacillus pleuropneumoniae. In herds with documented APP presence, vaccination significantly reduces the incidence of acute outbreaks characterized by sudden death, severe respiratory distress, and fever. The vaccines are particularly valuable during periods of high-risk such as post-weaning stress, commingling of animals from multiple sources, and seasonal periods when respiratory disease pressure typically increases. Prevention of acute mortality represents the most dramatic benefit of vaccination programs.

Beyond acute disease prevention, APP vaccines provide substantial value in reducing chronic production impacts associated with endemic APP infection. Subclinically infected herds experience persistent reduced growth rates, impaired feed efficiency, and increased susceptibility to secondary respiratory pathogens even when acute clinical outbreaks are absent. Vaccination helps limit these chronic impacts by reducing bacterial replication and toxin-mediated tissue damage, supporting more consistent and efficient growth performance throughout the finishing period.

Slaughter condemnation reduction represents an important economic indication for APP vaccination. Pleuropneumonia lesions, including pleuritis and pericarditis resulting from APP infection, lead to partial or complete carcass condemnation depending on severity and plant policies. These losses accumulate significantly in endemically infected herds, with some operations experiencing condemnation rates of several percent. Vaccination reduces both the incidence and severity of lung lesions, directly translating to improved carcass value realization.

In breeding herd applications, vaccination of gilts and sows provides passive protection to offspring through colostral antibody transfer. While passive immunity is temporary and does not replace active immunization of growing pigs, it provides early life protection during the vulnerable post-weaning period before active vaccination can be administered. This maternal antibody strategy is particularly valuable in herds with high APP challenge pressure where young pigs may encounter infection before age-appropriate vaccination.

Integration with comprehensive respiratory disease control programs represents the optimal use context for APP vaccines. Rather than functioning as standalone interventions, these vaccines work synergistically with biosecurity measures, environmental management, and control of other respiratory pathogens including PRRS virus, Mycoplasma hyopneumoniae, and swine influenza. This integrated approach recognizes that respiratory disease in commercial swine typically involves multiple pathogens and that optimal control requires addressing the entire disease complex.

Standard APP vaccination protocols typically involve a two-dose primary series administered by intramuscular injection, with specific timing varying by product and production system characteristics. The first dose is commonly administered at six to eight weeks of age, with the second dose given two to three weeks later. This timing positions peak immunity development during the post-weaning and early finishing periods when APP challenge risk is typically highest. The intramuscular route, typically targeting the neck muscles, ensures appropriate antigen presentation and immune stimulation.

Injection technique significantly impacts both vaccine efficacy and meat quality outcomes. Proper needle selection based on pig size prevents inadequate depth of injection in larger animals and excessive penetration in smaller pigs. Needle lengths of one-half to one inch are appropriate depending on animal size, with gauge selection balancing ease of injection against tissue trauma. Injection sites should be limited to the neck region to avoid creating lesions in valuable ham muscles that could result in trimming losses at slaughter.

Vaccine preparation requires thorough mixing before use, as adjuvanted products may settle during storage. Bottles should be shaken vigorously until contents appear homogeneous, with this mixing repeated periodically during vaccination sessions if product sits unused for extended periods. Vaccine should be brought to room temperature before administration to reduce injection site reactions and improve animal comfort. Cold vaccine administered directly from refrigeration may cause increased local tissue response.

Dose volume follows manufacturer specifications, typically two milliliters for most APP vaccine products. Accurate dosing requires properly calibrated vaccination equipment with regular verification of delivery volume. Multidose syringes should be checked for consistent delivery at the start of each vaccination session and periodically throughout use. Underdosing compromises immune response, while overdosing wastes product without providing additional protection and may increase adverse reaction incidence.

Breeding herd vaccination programs follow different schedules than growing pig protocols. Gilts are typically vaccinated twice during the development period, with some programs including a prepartum booster vaccination to enhance colostral antibody levels. Sow herds may receive annual or semi-annual boosters depending on herd APP status and vaccination program goals. These breeding herd programs require coordination with other reproductive vaccines and management events.

Withdrawal periods for APP vaccines are generally minimal or absent, as inactivated vaccines do not create tissue residue concerns comparable to pharmaceutical products. However, producers should verify specific product labeling for any withdrawal requirements and maintain vaccination records as part of overall food safety documentation. Injection site lesions, while not residue concerns, may be noted at slaughter inspection, emphasizing the importance of proper injection technique and appropriate timing relative to marketing.

Injection site reactions represent the most commonly observed side effect of APP vaccination, occurring in a percentage of vaccinated animals that varies by product formulation and individual animal response. Transient swelling at the injection site typically appears within twenty-four to forty-eight hours post-vaccination and resolves spontaneously over one to two weeks. The adjuvants included in inactivated vaccines to enhance immune response contribute to local inflammatory reactions, representing a trade-off between immunogenicity and injection site tolerance. Proper injection technique minimizes reaction severity.

Systemic reactions including transient fever, reduced feed intake, and decreased activity may occur in the hours to days following vaccination. These signs reflect normal immune system activation rather than concerning adverse effects and typically resolve within twenty-four to forty-eight hours. The incidence of systemic reactions is generally low with properly administered vaccine given to healthy animals. Animals demonstrating these signs rarely require treatment but should be monitored to ensure recovery progresses normally.

Anaphylactic reactions, while rare, represent the most serious potential adverse effect of APP vaccination. These immediate hypersensitivity responses can cause acute respiratory distress, cardiovascular collapse, and death if not promptly recognized and treated. Epinephrine should be available during vaccination sessions for emergency treatment of anaphylaxis. Animals with history of severe reactions to previous APP vaccination should not receive additional doses of the same product, and veterinary guidance should be sought regarding alternative approaches.

Reduced feed intake and transient growth check following vaccination may occur, particularly in young pigs receiving their primary vaccination series. This temporary setback typically resolves within several days and is generally outweighed by the protection benefits provided by vaccination. Some producers observe that vaccination during other stressful periods amplifies the transient performance impact, supporting strategies that avoid stacking multiple stressors when possible.

Chronic injection site lesions including sterile abscesses occasionally develop, particularly following inadvertent subcutaneous injection or contaminated equipment use. These lesions may persist to slaughter age and result in trimming losses. While not affecting animal health significantly, they represent both economic cost and animal welfare considerations that reinforce the importance of proper vaccination technique. Vaccination equipment should be maintained in clean condition with appropriate needle hygiene practices.

Clinically ill animals should not receive APP vaccination until health status has been restored. Sick pigs cannot mount optimal immune responses and may experience exacerbated adverse effects from vaccination during active illness. Animals demonstrating fever, respiratory distress, diarrhea, or other signs of systemic disease should be excluded from vaccination until clinical signs have resolved. This precaution applies regardless of the nature of the concurrent illness and reflects fundamental principles of vaccine immunology.

Animals with known hypersensitivity to APP vaccine components should not receive additional doses. While severe hypersensitivity reactions are uncommon, any animal demonstrating anaphylaxis or severe immediate reactions following previous APP vaccination should be excluded from future vaccination programs using the same product. Alternative vaccination strategies may be possible under veterinary guidance, potentially including different product formulations or altered vaccination protocols.

Recent treatment with immunosuppressive medications may impair vaccine response and represents a relative contraindication to vaccination. Corticosteroids at anti-inflammatory or immunosuppressive doses can significantly reduce antibody response to vaccination. Animals receiving such treatment should have vaccination delayed until an appropriate washout period has elapsed following medication discontinuation. The specific interval depends on the medication used and duration of treatment.

Vaccination during extreme stress conditions should be avoided when possible to ensure optimal immune response. Transport stress, abrupt diet changes, extreme temperatures, and concurrent disease outbreaks all impair immune function and may reduce vaccination effectiveness. While practical production constraints sometimes necessitate vaccination during suboptimal conditions, scheduling flexibility should be used when available to position vaccination during relatively low-stress periods.

Concurrent administration of multiple vaccines is common in swine production and generally poses limited interaction concerns with APP vaccines. Inactivated respiratory vaccines including Mycoplasma hyopneumoniae bacterins are frequently administered simultaneously with APP vaccines, using separate injection sites. Studies have generally demonstrated satisfactory immune responses to both antigens when administered concurrently, though some reduction in response to one or both vaccines may occur compared to separate administration. Practical production considerations often favor combined administration despite theoretical interaction potential.

Modified live virus vaccines present somewhat greater interaction uncertainty when administered with inactivated bacterial vaccines like APP products. The immune system activation patterns differ between live and inactivated vaccines, and concurrent administration may result in mutual interference. Some producers and veterinarians prefer separating live virus and inactivated bacterial vaccine administration by one to two weeks when production schedules permit. PRRS virus vaccines represent a common consideration given their widespread use and timing overlap with APP vaccination.

Immunosuppressive medications including corticosteroids at therapeutic doses can substantially impair antibody response to APP vaccination. Animals receiving such treatment for disease management should ideally complete medication courses and experience appropriate washout periods before vaccination. When treatment and vaccination schedules cannot be separated, reduced vaccine efficacy should be anticipated and additional management measures may be warranted to ensure protection.

Antibiotics commonly used in swine production do not directly interact with inactivated APP vaccines, as these products do not contain live bacteria susceptible to antimicrobial effects. However, metaphylactic or therapeutic antibiotic administration concurrent with vaccination may mask early clinical signs that would otherwise prompt treatment, creating a false impression of vaccine failure when breakthrough disease occurs. Additionally, some producers prefer separating antibiotic and vaccination events to simplify interpretation of any adverse effects observed.

Human safety precautions during APP vaccine administration focus on avoiding accidental self-injection and minimizing splash exposure. Accidental injection of adjuvanted veterinary vaccines can cause significant local tissue reaction including persistent granulomas. Personnel should maintain secure grip on both syringe and animal during injection to prevent erratic movement that increases self-injection risk. Safety syringes with needle shields reduce risk during disposal, which represents a high-risk moment for needle stick injuries.

Splash exposure to eyes or mucous membranes should be addressed immediately through thorough flushing with clean water. While inactivated vaccines do not cause infection, adjuvant components can cause irritation and inflammatory responses. Personnel with known allergies to vaccine components should avoid handling these products. Any concerning human exposure should be reported to a physician with information about the specific vaccine product involved.

Vaccine handling and storage directly impact product efficacy and must be managed carefully throughout the distribution chain. APP vaccines require continuous refrigeration at two to eight degrees Celsius and must never be frozen. Freezing disrupts the physical structure of adjuvanted products and may denature antigens, resulting in reduced or absent immunogenicity. Temperature monitoring during storage and transport provides documentation of appropriate handling and alerts to any cold chain failures.

Partially used multidose vials should not be stored for future vaccination sessions, as repeated needle entry increases contamination risk. Most manufacturers specify single-day use for opened containers. Any remaining vaccine should be discarded at the end of each vaccination session, and records should document lot numbers and expiration dates for all products used.

Antimicrobial stewardship principles support vaccination as a primary prevention strategy that reduces reliance on therapeutic and metaphylactic antibiotic use. Effective APP vaccination programs decrease the incidence of clinical disease requiring treatment and reduce chronic respiratory pathology that increases susceptibility to secondary infections. This preventive orientation aligns with industry and regulatory emphasis on judicious antimicrobial use and reduction of antibiotic consumption in food animal production.

Proper refrigerated storage of APP vaccines at two to eight degrees Celsius maintains product potency throughout the labeled shelf life. Vaccines should be positioned in refrigerators away from freezer compartments and cooling elements to prevent accidental freezing. Temperature monitoring devices should be used to verify appropriate storage conditions, with readings documented at least daily. Any temperature excursions outside the recommended range may compromise vaccine efficacy and should prompt consultation with the supplier regarding product viability.

Protection from light exposure supports vaccine stability, as some vaccine components may undergo photodegradation. Original packaging provides appropriate light protection during storage. Vaccines removed from refrigeration for use should be protected from direct sunlight during vaccination sessions. Extended exposure to light and elevated temperatures during field use should be minimized by returning products to cold storage during breaks in vaccination activities and avoiding preparation of more vaccine than can be administered within a reasonable timeframe.

Disposal of unused vaccine, empty containers, and used vaccination equipment requires attention to biosecurity and environmental considerations. While inactivated vaccines do not pose infectious disease risks, adjuvant components may cause local environmental effects if improperly disposed. Containers should be triple-rinsed before disposal through approved waste streams. Used needles require sharps disposal protocols to prevent human injury. Some jurisdictions have specific requirements for veterinary vaccine waste disposal that supersede general guidance.

Commercial swine genetics demonstrate generally consistent responses to APP vaccination across the major breed lines used in modern pork production. Yorkshire, Landrace, Duroc, Hampshire, and their crosses respond appropriately to standard vaccination protocols without need for breed-specific dose adjustments. The genetic uniformity of commercial swine populations, while creating concerns regarding disease susceptibility diversity, does simplify vaccination program design by eliminating major breed-specific considerations.

High-health breeding stock herds may employ different APP vaccination strategies than commercial growing pig operations. These herds often maintain APP-negative status through biosecurity and testing programs, making routine vaccination unnecessary and potentially counterproductive by introducing serological responses that complicate disease surveillance. When vaccination is used in breeding herds, gilt development protocols typically differ from sow maintenance programs, with multiple doses administered to establish solid immunity before entry into the breeding herd.

Sire lines selected for muscular development may warrant particular attention to injection technique and site selection to prevent lesions in valuable carcass cuts. While all pigs benefit from proper injection practices, the economic implications of injection site lesions are greatest in genetics selected for superior muscle mass. Consistent use of neck injection sites rather than ham muscles protects carcass value regardless of genetics.

Showpig and purebred breeding stock populations face unique considerations regarding vaccination records and health certification requirements. Breed registries and sales venues may have specific health documentation requirements that influence vaccination program design. These specialty populations may also encounter different APP serotype exposures depending on geographic distribution and movement patterns compared to commercial production populations.

Other respiratory vaccines commonly used alongside APP immunization include Mycoplasma hyopneumoniae bacterins and swine influenza virus vaccines. These products address different components of the porcine respiratory disease complex and are typically included in comprehensive vaccination programs for commercial growing pigs. Timing and administration of these vaccines may be coordinated with APP vaccination to minimize handling events while ensuring appropriate immune response to each antigen.

Combination vaccine products incorporating APP antigens with other respiratory pathogens offer convenience advantages by reducing the number of separate injections required. These products typically combine APP toxoids with Mycoplasma hyopneumoniae or Bordetella bronchiseptica antigens. While convenient, combination products may offer different antigen loads or serotype coverage compared to standalone APP vaccines, requiring careful product selection based on herd-specific disease challenges.

Therapeutic alternatives for APP control include antimicrobial medications effective against Actinobacillus pleuropneumoniae, including florfenicol, tulathromycin, ceftiofur, and various tetracyclines and macrolides. These therapeutic options address acute disease outbreaks and may be used strategically during high-risk periods. However, treatment cannot reverse lung damage from previous infection and does not provide the sustained protection achievable through vaccination. Integrated programs combining vaccination with strategic medication represent optimal approaches for herds facing significant APP challenge.